La cadena de opciones muestra datos clave de las opciones de acciones de Theriva Biologics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Theriva Biologics..

Theriva Biologics (AMEX:TOVX) Bolsa, Cadena de Opciones

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMPG

AVGR

BIPC

CHEK

CREV

FDSB

HSDT

KORE

LAES

LIND

NCRA

NEUE

NVNI

RELI

SLGL

TIVC

TLRY

TOVX

Carbon Revolution lidera con un aumento del 62,4% en el premercado. ¿Qué otras acciones destacaron antes de la apertura?

Las acciones de Carbon Revolution (CREV) están subiendo un 62%; 20 acciones que se están moviendo en el premercado

Theriva Biologics Inc

Guidance

Events

UnitedHealth Group Shares Rise As Company Begins Conference Call

Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) shares are trading higher after it reported first-quarter fiscal year segment revenues of $2.763 billion, up 8% year over year (Y/Y), beating <a href="https://www.benzinga.com/topic/stories-that-matter" target="_blank" rel="noreferrer noopener">the consensus of $2.689 billion</a>. 
Distributable earnings (DE) rose&nbsp;11% Y/Y to&nbsp;$1.41 billion. Fee-related earnings increased&nbsp;9% Y/Y to&nbsp;$1.26 billion.
Fee-related earnings fell&nbsp;17%&nbsp;Y/Y&nbsp;in real estate&nbsp;while rising&nbsp;26% Y/Y in the Credit &amp; Insurance business and&nbsp;51% Y/Y in the Private Equity segments.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/asset-sales/25/04/44646240/rogers-scores-5-billion-blackstone-deal-to-cut-debt-unlock-wireless-infrastructure-value" rel="noreferrer noopener">Rogers Scores $5 Billion Blackstone Deal To Cut Debt, Unlock Wireless Infrastructure Value</a>
Net accrued performance revenue rose to&nbsp;$6.40 billion in the quarter from&nbsp;$6.08 billion in the prior year quarter.
Distributable earnings per share of&nbsp;$1.09 (+11%&nbsp;Y/Y),&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$1.06</a>.
Asset under management rose&nbsp;10% Y/Y to&nbsp;$1.17 trillion, with inflows of&nbsp;$61.6 billion in the quarter.
Dividend: Blackstone declared a quarterly dividend per share of&nbsp;$0.93, payable on May 5, to shareholders of record as of April 28, 2025.
Buyback: The company repurchased 0.2 million shares in the first quarter, with $1.8 billion in available authorization remaining as of March 31, 2025.
As of March 31, 2024, Blackstone had&nbsp;$9.8 billion&nbsp;in total cash, cash equivalents, corporate treasury and other investments.
"Blackstone reported another quarter of strong results despite turbulent markets. Inflows reached $62 billion — the highest level in nearly three years — reflecting the deep trust we've built with our investors over decades. We also delivered positive investment performance across all of our major strategies,&#8221; said Stephen A. Schwarzman, chairman and CEO.
&#8221;We are well positioned to navigate the current environment with $177 billion of dry powder to deploy and a resilient, capital-light business model."
Investors can gain exposure to the stock via&nbsp;EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/LBO#BATS">LBO</a>) and&nbsp;Invesco Global Listed Private Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSP#NYSE">PSP</a>).
Price Action: BX shares are up 2.03% at $132.00 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44806734/marjorie-taylor-greene-made-large-stock-purchases-ahead-of-trumps-90-day-tariff-pause-hakeem-jeffries-calls-it-problematic" target="_blank" rel="noreferrer noopener">Marjorie Taylor Greene Made Large Stock Purchases Ahead Of Trump&#8217;s 90-Day Tariff Pause: Hakeem Jeffries Calls It &#8216;Problematic&#8217;</a></li>
</ul>
Photo: Shutterstock

Earnings

Equities

Large Cap

PowerShares Listed Private Equity Portfolio

Blackstone Beats Q1 Estimates, AUM Climbs to $1.17 Trillion, Inflows Hit 3-Year High

JP Morgan analyst Samik Chatterjee maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Overweight and lowers the price target from $73 to $70.

Price Target

Analyst Ratings

CSCO

JP Morgan Maintains Overweight on Cisco Systems, Lowers Price Target to $70

Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) is recalling 148,000 vehicles in the United States, the National Highway Traffic Safety Administration (NHTSA) said.
What Happened: In a statement on Thursday, the federal agency said that Ford is recalling 123,611 vehicles from the 2017–18 Ford F-150 series, the Ford Expedition, and Lincoln Navigator models. The recall is related to a fluid leak that affects the braking performance of these vehicles.
The auto safety regulator reiterated that dealers are expected to replace the affected parts, like the master cylinder or the brake booster, for no charge.
See Also: <a href="https://www.benzinga.com/25/04/44756759/new-research-shows-donald-trumps-25-tariffs-could-cost-auto-companies-108billion-report">Trump&#8217;s 25% Tariffs Could Cost Auto Companies $108 Billion: Report</a>
In a separate recall, the manufacturer is also fixing a Powertrain Control Module (PCM) on 24,655 2025 Ford Explorers. The issue could cause stalling of the vehicle or damage its parking system. Like above, the dealers are expected to fix the software issue for free.
Why It Matters: News of the recall comes in as Ford has indicated it <a href="https://www.benzinga.com/25/04/44857599/ford-could-hike-prices-of-its-vehicles-in-the-us-amid-auto-tariff-uncertainty-report">may hike the price</a> of its models in the U.S. as the company deals with the auto tariffs levied by the Trump administration.
Ratings agency S&amp;P had recently published a report, which said that Ford was at a <a href="https://www.benzinga.com/news/25/04/44806252/trump-tariffs-could-put-ford-gm-at-high-risk-of-negative-ratings-report">high risk of a negative rating</a> due to Trump's tariffs. The company currently boasts a BBB- rating.
However, Donald Trump's comments about providing some <a href="https://www.benzinga.com/25/04/44798727/auto-stocks-rise-on-trumps-comments-about-supporting-us-car-companies-whats-going-on">U.S. auto manufacturers with exemptions </a>to the tariffs could prove to be a relief for the Detroit-based company.&nbsp;
Price Action: F is currently trading at $9.40 on the NYSE, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44841871/lyft-expands-to-europe-with-e175m-freenow-acquisition-targets-bookings-by-e1b-annually">BMW, Mercedes-Benz Sell Taxi App To Lyft For $197M: CEO Says Entering Europe Is &#8216;Important Step&#8217;</a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock.com

Tech

General

Ford Recalls Nearly 150,000 Vehicles Over Brake And Powertrain Issues:  NHTSA

KZIA

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

JP Morgan analyst Samik Chatterjee maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Overweight and lowers the price target from $88 to $76.

CIEN

JP Morgan Maintains Overweight on Ciena, Lowers Price Target to $76

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) with a Outperform and raises the price target from $274 to $290.

Keefe, Bruyette & Woods Maintains Outperform on Travelers Companies, Raises Price Target to $290

Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: <a href="https://www.benzinga.com/stock/djt#Nasdaq,%20NYSE%20Texas">DJT</a>) ("TMTG" or "the Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, sent the following memo to the U.S. Securities and Exchange Commission:
MEMO: Suspicious Trading Activity of DJT Stock
To: Mark Uyeda, Acting Chairman, U.S. Securities and Exchange Commission From: Trump Media &amp; Technology Group
Date: April 17, 2025 Subject: Potential Illegal Naked Short Selling and Market Manipulation of DJT Stock
CC: Financial Industry Regulatory Authority (FINRA); Nasdaq; New York Stock Exchange
This letter serves to inform you of suspicious activity related to a disclosure filed in Germany by the U.K.-based hedge fund Qube Research &amp; Technologies ("Qube"). The following data points raise critical questions about the timing and methods used in Qube's trading activities:
<ul>
<li>On April 10, 2025, Qube disclosed a nearly six-million share short position in Trump Media &amp; Technology Group Corp ("TMTG") (NASDAQ, NYSE Texas: <a href="https://www.benzinga.com/stock/djt#NASDAQ,%20NYSE%20Texas">DJT</a>). Thus, a U.K.-based entity, with a data center in Iceland, only disclosed these short sales in Germany.</li>
<li>According to Nasdaq, the total short interest in DJT as of March 31, 2025, was 10.7 million shares (see attached chart). Third party sources inform TMTG that the total short interest as of April 16, 2025, is virtually unchanged—approximately 11 million shares.</li>
<li>Neither Nasdaq, NYSE Texas, nor any other source has been able to confirm when the trades disclosed by Qube were conducted or if they were conducted at all.</li>
</ul>

Legal

Trump Media And Technology Group Alerts SEC Of Potential Manipulation Of DJT stock

JP Morgan maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight and lowers the price target from $166 to $105.

JP Morgan Maintains Overweight on Celestica, Lowers Price Target to $105

WIIM

Kosmos Energy shares are trading higher after the company announced the first LNG cargo shipment at the Greater Tortue Ahmeyim project.

JP Morgan analyst Samik Chatterjee maintains CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) with a Neutral and lowers the price target from $222 to $175.

JP Morgan Maintains Neutral on CDW, Lowers Price Target to $175

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) with a Market Perform and lowers the price target from $130 to $115.

PNFP

Keefe, Bruyette & Woods Maintains Market Perform on Pinnacle Finl Partners, Lowers Price Target to $115

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Longbow Research analyst David Macgregor initiated coverage on Twin Disc, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWIN#NASDAQ">TWIN</a>) with a Buy rating and announced a price target of $12. Twin Disc shares closed at $6.66 on Wednesday. <a href="https://www.benzinga.com/quote/TWIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Blair Abernethy initiated coverage on RedCloud Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCT#NASDAQ">RCT</a>) with a Buy rating and announced a price target of $5. RedCloud shares closed at $1.71 on Wednesday. <a href="https://www.benzinga.com/quote/RCT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Eva Fortea Verdejo initiated coverage on Bicara Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) with an Underweight rating and announced a price target of&nbsp;$8. Bicara Therapeutics shares closed at $11.76 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo initiated coverage on Relay Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with an Equal-Weight rating and announced a price target of&nbsp;$4. Relay Therapeutics shares closed at $2.61 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Sam Eiber initiated coverage on Evolus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) with a Buy rating and announced a price target of $21. Evolus shares closed at $10.11 on Wednesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TWIN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-1024x593.png" alt="" class="wp-image-876433" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44857276/netflix-unitedhealth-group-and-3-stocks-to-watch-heading-into-thursday">Netflix, UnitedHealth Group And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Initiation

AMKR

BCAX

EOLS

RLAY

TWIN

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

JP Morgan analyst Samik Chatterjee maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Neutral and lowers the price target from $45 to $34.

CALX

JP Morgan Maintains Neutral on Calix, Lowers Price Target to $34

JP Morgan analyst Samik Chatterjee maintains Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Overweight and lowers the price target from $140 to $110.

ANET

JP Morgan Maintains Overweight on Arista Networks, Lowers Price Target to $110

Macro Economic Events

Economics

Federal Reserve

S&P 500 Futures Calm After Fed's Williams Reportedly Says On Fox Business; Monetary Policy Is Well Positioned, Doesn't See Need To Change Rates Any Time Soon, Tariffs Will Drive Up Inflation This Year And Lower Growth

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Nicolet Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIC#NYSE">NIC</a>) with a Market Perform and raises the price target from $115 to $118.

Keefe, Bruyette & Woods Maintains Market Perform on Nicolet Bankshares, Raises Price Target to $118

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup cut Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) price target from $162 to $138. Citigroup analyst Vikram Bagri upgraded the stock from Neutral to Buy. Generac shares closed at $110.65 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/GNRC/analyst-ratings">view this stock</a>.</li>
<li>Chardan Capital slashed the price target for Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) from $40 to $33. Chardan Capital analyst Daniil Gataulin maintained a Buy rating. Adverum Biotechnologies shares closed at $2.98 on Wednesday. See how other analysts<a href="https://www.benzinga.com/quote/ADVM/analyst-ratings"> view this stock</a>.</li>
<li>Rosenblatt cut Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) price target from $305 to $290. Rosenblatt analyst Chris Brendler maintained a Buy rating. Coinbase shares closed at $172.21 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">view this stock</a>.</li>
<li>Evercore ISI Group slashed the price target for Prologis, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) from $111 to $106. Evercore ISI Group analyst Steve Sakwa maintained an In-Line rating. Prologis shares closed at $100.29 on Wednesday. <a href="https://www.benzinga.com/quote/PLD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $289 to $297. B of A Securities analyst Joshua Shanker maintained a Neutral rating. Progressive shares closed at $275.13 on Wednesday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital slashed Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) price target from $105 to $64. BMO Capital analyst Evan David Seigerman downgraded the stock from Outperform to Market Perform. Novo Nordisk shares settled at $62.88 on Wednesday. <a href="https://www.benzinga.com/quote/NVO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co increased Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) price target from $29 to $32. HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating. Oculis Holding shares closed at $18.02 on Wednesday. <a href="https://www.benzinga.com/quote/OCS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Scotiabank raised Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) price target from $600 to $700. Scotiabank analyst Allan Verkhovski upgraded the stock from Sector Perform to Sector Outperform. Intuit shares closed at $588.08 on Wednesday.  <a href="https://www.benzinga.com/quote/INTU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised the price target for ServiceTitan, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) from $120 to $130. Canaccord Genuity analyst David Hynes maintained a Buy rating. ServiceTitan shares settled at $117.66 on Wednesday. <a href="https://www.benzinga.com/quote/TTAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods slashed Walker &amp; Dunlop, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) price target from $105 to $95. Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained an Outperform rating. Walker &amp; Dunlop shares closed at $73.65 on Wednesday. <a href="https://www.benzinga.com/quote/WD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying INTU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="604" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-1024x604.png" alt="" class="wp-image-876630" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-1024x604.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-768x453.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21.png 1088w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44857276/netflix-unitedhealth-group-and-3-stocks-to-watch-heading-into-thursday">Netflix, UnitedHealth Group And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

ADVM

COIN

GNRC

INTU

TTAN

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Empowering Companies to Meet Rising Global Demand for Circular, Transparent, and Efficient Plastics
NEW YORK, NY / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 17, 2025 / SMX (Security Matters) PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXWW#NASDAQ">SMXWW</a>), a pioneer in digitizing physical objects for a circular economy, announces a strategic collaboration with Aegis Packaging, a Singapore-based leader in high-barrier coatings for flexible plastic packaging. This alliance merges SMX's invisible molecular marking and blockchain-based platform with Aegis Packaging's O₂X&#x2122; coating technology offering a seamless way to enhance the recyclability and verifiability of plastic packaging

SMXWW

SMX Announces Strategic Collaboration With Aegis Packaging To Meet Rising Global Demand For Circular, Transparent, And Efficient Plastics

Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintains Fulton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) with a Market Perform and lowers the price target from $24 to $21.

FULT

Keefe, Bruyette & Woods Maintains Market Perform on Fulton Financial, Lowers Price Target to $21

Press Releases

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Health Care

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Aditxt

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Organovo Holdings

Palisade Bio

Plus Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Sunshine Biopharma

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Xenetic Biosciences

Maxim Group

Screenshot 2024-08-23 at 5.34.20 PM

Biotech

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-28 at 6.54.06 PM

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Comments

Theriva Biologics

Theriva Biologics (TOVX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL